654. Multiple Myeloma: Pharmacologic Therapies: Poster I

Trial in progress CAR T idecabtagene vicleucel in advanced myeloma plus iberdomide or usual monitoring The Alliance A062102 CADMIUM Study

A Phase 2 3 multicenter randomized open label study evaluating the efficacy and safety of etentamig and daratumumab compared to daratumumab lenalidomide and dexamethasone in frailer transplant ineligible patients with newly diagnosed multiple myeloma

Real world sequencing of anti BCMA CAR T cells and bispecific T cell engagers in Relapsed Refractory multiple myeloma A multi country analysis

Daratumumab bortezomib thalidomide and dexamethasone improves renal outcomes in multiple myeloma transplant eligible patients presenting with renal failure A real life experience from northeastern Italy

An exploratory analysis of health related quality of life measures with belantamab mafodotin in combination with pomalidomide and dexamethasone BPd in patients with relapsed or refractory multiple myeloma RRMM enrolled in dreamm 8

Impact of tumor burden on the risk of cytokine release syndrome CRS in patients with multiple myeloma treated with elranatamab ELRA in combination with daratumumab DARA and lenalidomide R in the MagnetisMM 6 trial

Talquetamab a GPRC5D×CD3 bispecific antibody in combination with pomalidomide in patients with Relapsed Refractory multiple myeloma Updated safety and efficacy results from the Phase 1b monumental 2 study

Phase 2 study of aponermin kt decp in patients pts with Relapsed Refractory multiple myeloma and extramedullary disease

Updated results of TQB2934 a novel 2 1 BCMA × CD3 bispecific antibody in patients with relapsed refractory multiple myeloma A phase I study

GT919 a novel IKZF3 1 molecular glue degrader Phase 1 safety and preliminary efficacy in relapsed or refractory multiple myeloma R R MM

Survival impact of anti CD38 based quadruplet regimens in transplant ineligible newly diagnosed multiple myeloma A network meta analysis and reconstructed individual patient data meta analysis

Aponermin combined with carfilzomid pomalidomide dexamethasone KPd in patients with relapsed or refractory multiple myeloma A prospective open label multicenter study

MBS314 a GPRC5DxBCMAxCD3 trispecific antibody in relapsed refractory multiple myeloma RRMM Updated results from a Phase 1 dose escalation study

Impact of previous BCMA exposure Evidence from practice outside of clinical trials to inform talquetamab sequencing

Efficacy and safety of aponermin carfilzomib dexamethasone based regimens for relapsed refractory multiple myeloma A Phase 2 prospective multi center study

Safety and efficacy of aponermin based chemotherapy as bridging therapy before CAR T cell treatment in relapsed refractory multiple myeloma

Prolonged elranatamab treatment interruption in patients with relapsed or refractory multiple myeloma RRMM is feasible A retrospective analysis from MagnetisMM 3

Clonotypic peptide mass spectrometry to monitor m protein reduction in patients with relapsed refractory multiple myeloma from ikema Study

Efficacy and safety of isa vrd in elderly patients with or without frailty criteria Pooled analysis of imroz and phase 1b studies in newly diagnosed multiple myeloma patients

Restarting etentamig therapy after dosing delays or interruptions Population pharmacokinetics PopPK and PK PD simulations and supporting clinical data

Patients with Relapsed Refractory multiple myeloma who achieved sustained minimal residual disease negativity in the dreamm 7 trial

Deep responses and durable outcomes in patients treated with belantamab mafodotin plus pomalidomide and dexamethasone from long term follow up of the Phase 3 dreamm 8 study

Long term responders from the Phase 3 dreamm 7 study of belantamab mafodotin plus bortezomib and dexamethasone vs daratumumab plus bortezomib and dexamethasone in Relapsed Refractory multiple myeloma

Maintenance therapy discontinuation for patients diagnosed with multiple myeloma without high risk features in minimal residual disease MRD negative remission An interim analysis

Impact of belantamab mafodotin–containing regimens on renal function in patients with Relapsed Refractory multiple myeloma RRMM and mild moderate renal impairment in the dreamm 7 and dreamm 8 trials

T cell engager activity of etentamig BCMA x CD3 is potentiated by daratumumab in preclinical models of multiple myeloma

Randomized comparison between isatuximab rd versus rd induction followed by isa R versus R maintenance in very elderly patients with NDMM Efficacy data on MRD after induction AGMT MM04 Trial

Carfilzomib Augmented with high dose melphalan conditioning regimen Enhances Response in patients with multiple myeloma eligible for ASCT an investigator initiated prospective multicenter study

Longitudinal analysis of MRD negativity and immune dynamics in patients with transplant ineligible newly diagnosed multiple myeloma treated with iberdomide daratumumab and dexamethasone from the CC 220 MM 001 trial

Safety and efficacy of linvoseltamab LINVO combined with anti CD38 monoclonal antibodies mAbs daratumumab DARA or isatuximab ISA in patients pts with relapsed refractory multiple myeloma RRMM Initial results from the multicohort Phase 1b LINKER MM2 trial

A clinical overview of infection in patients receiving elranatamab ELRA in combination with daratumumab DARA and lenalidomide R for newly diagnosed multiple myeloma in the MagnetisMM 6 trial